文献速递前列腺增生与排尿功能障碍

奥那肉毒毒素A与索利那新对比安慰剂在索利那新初治的难治性膀胱过度活动症患者中的疗效与安全性:多中心、随机、双盲3b期试验结果

The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
PubMed 文献 · J Urol · 2017-02-01

本多中心随机双盲3b期试验纳入索利那新初治的膀胱过度活动症伴尿失禁且抗胆碱能治疗反应不足或不耐受的患者,随机接受奥那肉毒毒素A 100 U、索利那新5 mg(第6周可按预设标准升至10 mg)或安慰剂。第12周奥那肉毒毒素A和索利那新的尿失禁发作减少均显著优于安慰剂,奥那肉毒毒素A优于索利那新;奥那肉毒毒素A组尿路感染和尿潴留更常见。

要点

  • 奥那肉毒毒素A和索利那新减少每日尿失禁发作均显著优于安慰剂。
  • 奥那肉毒毒素A减少尿失禁显著优于索利那新,约三分之一患者达到完全干爽。
  • 奥那肉毒毒素A组尿路感染25.5%、尿潴留6.9%更常见。

核心结论

  • 奥那肉毒毒素A和索利那新的疗效显著高于安慰剂,奥那肉毒毒素A较索利那新显著减少尿失禁,约三分之一患者达到100%尿失禁减少,未观察到意外安全信号。

研究设计与样本

  • 多中心、随机、双盲3b期试验,纳入索利那新初治的膀胱过度活动症伴尿失禁且对抗胆碱能药物反应不足或不耐受的患者,随机接受奥那肉毒毒素A 100 U、索利那新5 mg(第6周可按预设标准升至10 mg)或安慰剂。

主要发现

  • 每日尿失禁发作较基线变化:奥那肉毒毒素A组-3.19、索利那新组-2.56、安慰剂组-1.33,两个活性治疗组对比安慰剂均p<0.001。
  • 奥那肉毒毒素A组尿失禁减少显著优于索利那新组(p=0.022)。
  • 第12周干爽(尿失禁发作100%减少)比例:奥那肉毒毒素A组33.8%(对比安慰剂p<0.001)、索利那新组24.5%(对比安慰剂p=0.028)、安慰剂组11.7%。
  • 开放标签奥那肉毒毒素A再次治疗后干爽比例:奥那肉毒毒素A组43.2%、索利那新组37.6%、安慰剂组41.9%。
  • 两种活性治疗均观察到其他泌尿症状和生活质量显著改善;奥那肉毒毒素A组尿路感染25.5%、尿潴留6.9%更常见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this double-blind, randomized study we compared the efficacy and safety of onabotulinumtoxinA or solifenacin vs placebo in patients with overactive bladder who had urinary incontinence and an inadequate response to or were intolerant of an anticholinergic. Post hoc analysis was done to compare the effects of onabotulinumtoxinA vs solifenacin. MATERIALS AND METHODS: Solifenacin naïve patients were randomized to onabotulinumtoxinA 100 U, solifenacin 5 mg, (which could escalate to 10 mg at week 6 according to predefined criteria) or placebo. Patients could request treatment 2 (open label onabotulinumtoxinA) after fulfilling prespecified criteria. End points included a change from baseline in the number of urinary incontinence episodes per day and the proportion of patients with a 100% reduction (dry) in the number of incontinence episodes per day as co-primaries, other urinary symptoms and quality of life, all at week 12, and adverse events. RESULTS: The change from baseline in incontinence episodes per day was significantly greater with onabotulinumtoxinA or solifenacin vs placebo (-3.19 or -2.56, respectively, vs -1.33, both p <0.001). The incontinence reduction was significantly greater for onabotulinumtoxinA vs solifenacin (p = 0.022). At week 12, 33.8% (vs placebo p <0.001), 24.5% (vs placebo p = 0.028) and 11.7% of patients receiving onabotulinumtoxinA, solifenacin and placebo, respectively, were dry. After treatment 2, which was open label onabotulinumtoxinA, 43.2%, 37.6% and 41.9% of patients in the onabotulinumtoxinA, solifenacin and placebo groups, respectively, were dry. Significant improvements in other urinary symptoms and quality of life were observed for both active treatments. Urinary tract infection in 25.5% of cases and urinary retention in 6.9% were more common with onabotulinumtoxinA. CONCLUSIONS: The efficacy of onabotulinumtoxinA and solifenacin was significantly higher than that of placebo. However, onabotulinumtoxinA showed significantly greater decreases in urinary incontinence than solifenacin with a third of patients achieving a 100% incontinence reduction. No unexpected safety signals were observed.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Herschorn S, Kohan A, Aliotta P, et al. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. J Urol. 2017. PMID: 28161352. doi:10.1016/j.juro.2017.01.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。